Jade Biosciences, Inc.
NASDAQ Global MarketTotal Valuation
Jade Biosciences, Inc. carries a market capitalization of 879.55M, placing it among publicly traded companies globally. Its enterprise value stands at 951.64M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 879.55M |
| Enterprise Value | 951.64M |
Share Statistics
Jade Biosciences, Inc. currently has 63.56M shares outstanding.
| Shares Outstanding | 63.56M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 3.21 |
| P/TBV Ratio | 3.21 |
| P/FCF Ratio | -9.51 |
| P/OCF Ratio | -9.50 |
Financial Position
Jade Biosciences, Inc. maintains a current ratio of 14.93, meaning it holds 14.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 14.93 |
| Quick Ratio | 14.61 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -47.78 |
| Return on Assets (ROA) | -44.03 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
| Income Tax | 31,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
Jade Biosciences, Inc.'s stock has gained approximately 38.3% over the past 52 weeks. The 50-day moving average sits at 17.99, while the 200-day moving average is 18.20.
| Beta (5Y) | N/A |
| 52-Week Price Change | 38.3% |
| 50-Day Moving Average | 17.99 |
| 200-Day Moving Average | 18.20 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -164.70M, while operating income came in at -164.74M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -164.74M |
| Pretax Income | -153.15M |
| Net Income | -153.24M |
| EBITDA | -164.70M |
| EBIT | -164.74M |
| Earnings Per Share (EPS) | -2.90 |
Balance Sheet
Jade Biosciences, Inc. holds 461.21M in cash and equivalents against 628,000.00 in total debt, resulting in a net debt position of -107.25M. Total book value stands at 439.91M, with working capital of 439.68M providing operational flexibility.
| Cash & Cash Equivalents | 461.21M |
| Total Debt | 628,000.00 |
| Net Debt | -107.25M |
| Equity (Book Value) | 439.91M |
| Book Value Per Share | 6.92 |
| Working Capital | 439.68M |
Cash Flow
Jade Biosciences, Inc. produced -123.51M in operating cash flow over the past twelve months. After subtracting -60,000.00 in capital expenditures, free cash flow totaled -123.57M - equivalent to -2.34 per share.
| Operating Cash Flow | -123.51M |
| Capital Expenditures | -60,000.00 |
| Free Cash Flow | -123.57M |
| FCF Per Share | -2.34 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -25.70 |
| FCF Yield | -10.52 |
Stock Splits
Jade Biosciences, Inc.'s most recent stock split took place on April 29, 2025 with a 35:1 split ratio.
| Last Split Date | 4/29/2025 |
| Split Ratio | 35:1 |
Scores
Jade Biosciences, Inc. posts an Altman Z-Score of 25.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 25.48 |